Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F7YW
|
|||
| Former ID |
DIB004097
|
|||
| Drug Name |
MGN-1703
|
|||
| Synonyms |
TLR-9 agonist (cancer), Mologen
Click to Show/Hide
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 3 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1 | [2] | ||
| Company |
Mologen Holding AG
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02077868) Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol. 2014 Sep;140(9):1615-24. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.